ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KRSA vs AAPG // GROSS PROFIT MARGIN

Korsana Biosciences Inc. (NASDAQ) VS. Ascentage Pharma Group International American Depository Shares (NASDAQ) • 15-METRIC TALLY: KRSA 1 — AAPG 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRSA VS. AAPG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KRSA AAPG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -5.70% — — TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.24% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) 3.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 — — TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.6 42.1 +3.50 KRSA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.38B $1.39B -$12.5M AAPG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KRSA REV AAPG REV KRSA GROSS % AAPG GROSS % KRSA FCF AAPG FCF
FY 2025 $2.1M — — — -$3.3M —
FY 2024 $2.0M — — — -$4.3M —
FY 2023 $0 — — — -$21.2M —
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRSA // BETA —
AAPG // BETA —